This website uses cookies to help us improve the website and give you the best experience.
By using the website you agree to our use of cookies. Read more

X
You appear to be from the USA. Would like to proceed to Products available in the USA?
   

The value of PINP measurements in the diagnosis and treatment of osteoporosis

Osteoporosis is a medical condition in which the bones become fragile from loss of bone mass. Osteoporosis is caused by a disturbance in the normal turnover process of bone, typically as a result of hormonal changes, or deficiency of calcium or vitamin D. Consequently it leads to an increased risk of bone fractures.

Diagnosis of osteoporosis is often done by measuring the bone mineral density (BMD) of the patient. BMD is though a static measure of the patient’s current bone status and therefore provides no information about the rate of bone turnover, that is, how fast bone turnover is taking place. As increased bone turnover is associated with an increased risk of fracture, the assessment of bone turnover will provide valuable complementary data on the patient’s bone status.

Bone turnover in the patient can be determined by measuring PINP concentrations with the UniQ PINP kit in the patient’s blood. The measurement of PINP is a sensitive means of assessing bone turnover. The level of PINP has been found to correlate1 with and precede changes in BMD, and to predict the rate of bone loss2. When BMD is used to monitor the effect of antiresorptive or anabolic therapy in osteoporosis, it usually takes two years of therapy before a significant response in BMD can be detected. With PINP, similar information can be obtained rapidly, in a couple of months, after the onset of therapy3. PINP therefore provides early information concerning the response to osteoporosis treatment4 and aids in selection of the right treatment option. Measurements of PINP can also be used to encourage patient compliance5.

 Reference

  1. Tähtelä R et al. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos Int 2005;16:1109-1116.
  2. Garnero P et al. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999;14:1614-1621.
  3. Burnett-Bowie S et al. Prediction of changes in bone mineral density of postmenopausal women treated with once-weekly bisphosphonates. J Clin Endocrinol Metab 2009;94:2915-2921.
  4. Miyauchi A et al. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12 month open-label phases. Bone 2010;47:493-502.
  5. Eastell R et al. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006;22:61-66.

Read more:

UniQ PINP

UniQ_PINP_RIA_Open_Kit_web

Published September 30, 2016